Notice: Educational content. This site contains affiliate links — we may earn commission at no extra cost to you. Not medical advice. Consult your physician before starting any medication.
GLP-1 Evolution
🇺🇸 EN 🇪🇸 ES
Phase 3 Topline Data

TRIUMPH-4 Trial Results: Retatrutide Phase 3 Data 2026 (Honest Breakdown)

Status update — September 20, 2026

Retatrutide remains investigational and NOT FDA-approved; in Lilly’s words it “cannot be legally sold or marketed for human use” (press release, July 23, 2026). Lilly has announced topline Phase 3 results by press release — TRIUMPH-4 (Dec 11, 2025; 28.7% mean weight loss at 12 mg vs 2.1% placebo, 68 weeks), TRIUMPH-1 (May 21, 2026; 28.3% vs 2.2%, 80 weeks), TRIUMPH-2 and TRIUMPH-3 (Jul 23, 2026; 20.8% and 22.6%) — which are company-reported and not yet peer-reviewed. The only peer-reviewed Phase 3 publication is TRANSCEND-T2D-1 in type-2 diabetes (The Lancet, June 2026, PMID 42250575). Lilly says it plans to submit a Biologics License Application (BLA) in Q1 2027 — a company projection, not an FDA decision or date. TRIUMPH-2 is scheduled for presentation at EASD 2026 (Milan, Sep 28–Oct 2), a future presentation as of this update.

Separately, two oral GLP-1 medicines are now FDA-approved for weight management: Wegovy tablets 25 mg (Dec 22, 2025) and Foundayo (orforglipron, Apr 1, 2026; maximum 17.2 mg once daily). Earlier estimates on this page that predate these announcements are kept for context. Sources: investor.lilly.com; ClinicalTrials.gov NCT05929066, NCT05929079, NCT05882045, NCT05931367 (completed; results not yet posted).

Updated 2026-05-06 · 12 min read · Sources peer-reviewed where available

Eli Lilly's late-2025 / early-2026 corporate disclosures pointed to ~28.7% body-weight reduction in the highest-dose arm of TRIUMPH-4 — the Phase 3 retatrutide trial. A secondary readout flagged ~75.8% reduction in knee pain within the osteoarthritis sub-population. These numbers are real, but they require context. Below is the honest breakdown — what's confirmed, what's still pending peer review, and what it actually means for the FDA approval timeline.

TL;DR — 7 facts that matter

What is TRIUMPH-4?

TRIUMPH-4 (ClinicalTrials.gov identifier NCT05882045) is one of the Phase 3 trials in Eli Lilly's retatrutide program. The trial enrolled adults with obesity (BMI ≥30) and concurrent knee osteoarthritis — a deliberately chosen population because GLP-1/GIP/glucagon triple agonism is hypothesized to address both metabolic dysfunction and inflammation-driven joint pain.

Sample size, duration, and detailed inclusion criteria are publicly available on ClinicalTrials.gov. Primary endpoint: change in body weight from baseline. Co-primary or secondary: change in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score and physical function metrics.

TRIUMPH-4 is one piece of a broader Phase 3 program (TRIUMPH-1 through TRIUMPH-5) that Eli Lilly will eventually pool for the New Drug Application (NDA) submission to the FDA.

What the topline data shows

Reported topline figures (Eli Lilly disclosures)

Sources: Eli Lilly investor communications and topline press releases. Peer-reviewed publication in a major journal (NEJM, Lancet, JAMA) typically follows 6-18 months after topline disclosure.

The 28.7% figure is striking. By comparison, Phase 3 trials of semaglutide (Wegovy) showed ~15% body-weight reduction in obesity (STEP-1, Wilding et al, NEJM 2021, PMID 33567185). Tirzepatide (Zepbound/Mounjaro) showed ~21% in SURMOUNT-1 (Jastreboff et al, NEJM 2022, PMID 35658024). Retatrutide's triple-receptor mechanism (GLP-1 + GIP + glucagon) was hypothesized to push the curve further — and the data appears to validate that hypothesis.

🔔

Get notified the day FDA approves retatrutide

We track NDA submissions, advisory committee dates, and approval announcements — daily. Free, no spam.

How TRIUMPH-4 compares to Phase 2

Phase 2 retatrutide data is the closest peer-reviewed reference. Jastreboff et al, NEJM 2023 (PMID 37364103; DOI 10.1056/NEJMoa2301972) reported ~24% mean body-weight reduction at 48 weeks in adults with obesity, highest-dose arm.

The Phase 3 TRIUMPH-4 topline of 28.7% is roughly 4-5 percentage points higher than Phase 2 — within the expected range when (a) extending trial duration, (b) refining the dosing schedule, and (c) selecting the optimal patient population. It is not a leap that demands skepticism; it is consistent with what the mechanism of action would predict.

What TRIUMPH-4 does not mean

Timeline ahead

Based on Eli Lilly's typical regulatory cadence and investor commentary, the realistic timeline (all estimated, not promised) is:

  1. 2026 (in progress): Phase 3 program reads out across TRIUMPH-1 through TRIUMPH-5. Full peer-reviewed publications begin.
  2. Q1 2027 (Lilly’s stated plan): BLA submission to FDA (press release, July 23, 2026).
  3. 2027 (estimated): FDA review. Standard review = 10 months from NDA acceptance; Priority Review = 6 months. Whether retatrutide gets Priority designation is unknown.
  4. 2027 (possibly): Advisory Committee meeting, if FDA requires one. For obesity drugs in this class, AdCom is not always called.
  5. 2027-2028 (estimated): Earliest commercial launch. Branded retatrutide enters pharmacies. Initial supply will likely be constrained — see the Wegovy/Zepbound launch precedent.

Track every milestone live on our Retatrutide FDA Approval Tracker — bookmarked update on every official disclosure.

How readers can prepare

  1. Subscribe to the waitlist (form above). We email subscribers ONLY when something material happens — Phase 3 publication, NDA submission, AdCom date, approval, or supply constraint announcements. No daily newsletter spam.
  2. Bookmark the FDA Approval Tracker at /retatrutide-approval-tracker.html — updated as official events happen.
  3. Talk to your physician about whether a currently-approved GLP-1 or GLP-1/GIP option (semaglutide, tirzepatide) is appropriate for you while retatrutide moves through approval. If you're exploring legal options today, compare vetted telehealth providers in our honest 2026 reviews — e.g. SHED (premium concierge) — and see real pricing in our retatrutide cost breakdown. (Affiliate links — see disclosure.)
  4. Read the full Phase 2 paper when you have time — Jastreboff 2023 NEJM is available open-access on PubMed.
  5. Be skeptical of any "buy retatrutide" offer in 2026. The molecule is not yet legally available. Sellers are either lying about what's in the vial or operating outside compliance.

Frequently asked

Is retatrutide FDA-approved after TRIUMPH-4?

No. As of September 20, 2026, retatrutide is still investigational. TRIUMPH-4 is a Phase 3 trial; FDA approval requires NDA submission, FDA review, and (potentially) advisory committee. Earliest approval estimated 2027-2028 — speculative.

Where can I buy retatrutide after the TRIUMPH-4 results?

Nowhere legally. Retatrutide is not yet FDA-approved and not legally available for sale in 2026. Any vendor selling "retatrutide" is operating outside FDA-approved channels. We do not link to any such vendor.

Has TRIUMPH-4 data been peer-reviewed?

The 28.7% topline weight-loss figure was disclosed by Eli Lilly in late 2025 / early 2026 corporate communications. Full peer-reviewed publication in NEJM or Lancet typically follows 6-18 months later. Always wait for peer review before drawing strong conclusions.

How does TRIUMPH-4 compare to Phase 2?

Phase 2 (Jastreboff et al, NEJM 2023, PMID 37364103) showed ~24% weight loss at 48 weeks in obesity. Phase 3 TRIUMPH-4 topline of 28.7% is consistent or slightly higher — within expected range when extending duration and refining dosing. Final Phase 3 paper will provide statistical context.

Sources & clinical references

Disclaimer: Educational content only. Not medical advice. Retatrutide is investigational and NOT FDA-approved. Topline trial data is preliminary and not yet peer-reviewed. Individual results vary significantly. Consult your physician before starting any medication.